My Authors
Read all threads
-A HYDERABAD based pharma co. having presence in 4 VERTICALS - API’S, GENERIC–FDF(fixed dosage formulations), Synthesis and Ingredients.
- founded by Dr. Satyanarayana Chava (CEO) around 2007
- R&D spend 5.7% of Rev.
-750+ scientists and 50+ PHDs
-Carries out its operations through 6 plants – all USFDA approved except UNIT-5 (CDMO) which is a dedicated Hormone and Steroid facility for ASPEN PHARMA.
- Total capacity 3615 KL, 751 reactors and 5 billion tablet capacity
-65% is export revenue and 35% is domestic revenue REVENUE BREAKUP In Rs.Mn
- UNIT1 & 3 contibutes 80% of topline.
- Unit-2 is sole US formulations facility wid capacity of 5 bn tabs/capsules per yr also undergoing expansion which will be operational by Sept’20.
-Unit-6 is for captive API consumption
-Co. had aggressively expanded its capacities in d past & low utilization along with higher Raw material prices affected its profitability in FY18-19.
-With inc. orders n optimal utilization of its FDF facility, bckwrd integr. of their key API’S Co hs been able to get bk on track
1.Generic –FDF (29%OF FY20 Rev. from 2% OF FY19)
-development and manufacture of oral solid formulations.
-expected to be a key growth driver going ahead.

We can further divide FDF business under two heads:
i.Tender Driven ii.Non Tender
i.Tender Driven- In 2019 Co. rcvd d tender frm Global Fund fr Supply of HIV drug TLD for 3.5yrs.
TLD- Is a combo of tenofovir (TDF 300mg), lamivudine (3TC 300mg) and dolutegravir (DTG 50 mg).
-TLD Rev potential~$150mn(1125cr) from TLD tenders during FY20-22 TLD COMPETITORS
-After WHO changed its guidelines for 1st Line Regimen for HIV from TLE(Efavirenz) to TLD, Demand for TLD is expected to inc.
-Apart frm TLD it also produces TLE400/600 (Efavirenz) which was earlier 1st line regimen for HIV & now is most preferred after TLD.
-It hs recently rcvd USFDA App.under PEPFAR for TLE 400 (Tenofovir/ Lamivudine/ Efavirenz - 300/300/400mg) & TLE 600 tabs.
-Apart frm Laurus, only 2 players- Mylan 7 Macleods currently hv tentative USFDA app./WHO PQ fr d same.
-It mfgs all 4 imp. mol for ARV's.(DTG,3TC,EFV,TDF)
-TLE400/600-can contribute 135cr/210cr widout participation in global tenders.
-There is price pressure in this seg. But patient base is inc therefore high vol. r expected.
-Laurus can compete in prices & maintain margins bcoz of its backward integration of key API’S
ii) NON TENDER–Contributes 20% of its total FDF buss.,which is split equally betwn d US & Europe.
-Metformin-Co. hs 4% mkt share in Metformin
-Pegabalin- high teen mkt share
-Launched Hydroxychloroquine in US (Mar 2020)
-Also looking to mfg REMDESIVIR & FAVIPIRAVIR.
Overall outlook fr FDF buss. luks gud & acc to mgt they r working at PEAK capacity utilization wid a healthy order book & target to double FDF capacity by FY2022 speaks a lot.

2.GENERIC API’S-57% of Rev.
-60+Commercialized API’S in d area of ARV, ONCOLOGY, Anti-Diabetic,hepC etc
-API buss comprises d development, mfg & sale of APIs and adv intermediates.
-FY20 saw a 28% decline in revenues from API due to lower off-take of Efavirenz(EFV) and FTC APIs.
-Dolutegravir(DTG) in TLD is fast replacing Efavirenz in most of African market
-Growth will be driven by Lamivudine(3TC) and Dolutegravir(DTG)
-They also completed filing of 2nd line ARV API of Lopinavir and Ritonavir
-Co. is undergoing expansion in all Main APIs
Projected capacity expansion prog. for its main APIs.
NON ARV API’S-Has significant mkt share in Gemcitabine.
-Carboplatin is another important oncology molecule.
-Onco APIs Rev. Rs 210cr in FY20.
-Total Non ARV Rev Rs.320cr in FY20 (+54%YOY).
Good growth is expected in API seg. as co. has healthy order book.
-includes contract development and mfg services for global pharmaceutical co’s.
-contributed Rs.385cr for FY20 vs Rs.294cr (+30%)
-This buss. Can be profitability driver going ahead as it generates better EBITDA margins
-Grown 4x in 5yrs
-Unit 5(125KL) is dedicated facility for ASPEN for mfg of hormonal and steroid inter.
-Out of 30-40 Active projects 1 is intermediate COMMERCIALIZED & 2 r in PHASE-3
-Added a dedicated block at UNIT-4 for C2PHARMA for contract mfg of HIGH value APIs.
-Recently they got validation for DIGOXIN API for C2Pharma.

CAPEX- after undergoing capex in last few yrs mgt is still going ahead with Rs.300cr capex for FY21 for expanding capacities in formulations & debottlenecking of existing formulation facilities .
-Long-term plan to expand API capacity from current 4mn liter to 5mn liter reactor capacity
-Doubling of FDF Capacity

NOTE:In last 7 yrs it has already inc its fixed assets by 3.5x from 499cr to 1726crs
Risks-1.Lumpiness of Synthesis Buss.
2.Efavirenz (ARV) offtake might take a hit due to change in WHO guidelines.
3.Pricing pressure in ARV tender Buss.
4.Raw mat sourcing from China at 50%, though it is coming down but still can effect in short term.
5. Promoter Pledge @31.56% has come down from 45.22% but Individual Promoter Level Pledge still at 45%.

Could not share any financial info otherwise thread wud hv bcome more longer.Tried to make it as short as poss.
In case of any mistake in d info do correct me.

Promoters released pledge on 25lac shares.
Pledged shares wrt total share cap now stands at 7.32% only.

Missing some Tweet in this thread? You can try to force a refresh.

Keep Current with Aditya Mehta

Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

Twitter may remove this content at anytime, convert it as a PDF, save and print for later use!

Try unrolling a thread yourself!

how to unroll video

1) Follow Thread Reader App on Twitter so you can easily mention us!

2) Go to a Twitter thread (series of Tweets by the same owner) and mention us with a keyword "unroll" @threadreaderapp unroll

You can practice here first or read more on our help page!

Follow Us on Twitter!

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3.00/month or $30.00/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!